October 28, 2019 08:04 AM EDTUpdated October 29, 07:38 AM
R&D

Mixed ear­ly da­ta on Agios' AG-270 sug­gest com­bo ther­a­py could be way for­ward

Natalie Grover

Reporter

As Agios sus­pect­ed, the pro­file of its ex­per­i­men­tal drug AG-270 is like­ly tai­lored best as part of a com­bi­na­tion ther­a­py.

On Sun­day, the drug­mak­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times